Table 2 |.

Selected clinical trials involving neoadjuvant ADT with pCR rates reported

Study	n	Predefined study entry criteria in manuscript					Treatment arm(s)	pCR rate	MRD (≤ 5 mm)	MRD (<0.25 cm3)	pCR defined?	MRD defined?
		T-stage	Gleason score	Number of cores	Baseline PSA	Imaging criteria
Labrie et al. (1997)110	161	Yes	No	No	No	No	Leuprolide + flutamide for 3 months	7%	NA	NA	No	No
Van Der Kwast et al.(1999)111	47	No	No	No	No	No	Leuprolide + flutamide for 3 months	0%	NA	NA	No	No
							Leuprolide + flutamide for 6 months	9%
G leave et al. (2001)112	547	No*	No	No	No	No	Leuprolide + flutamide for 3 months	5%	NA	NA	Yes	No
							Leuprolide + flutamide for 8 months	9%
Klotz et al. (2003)113	213	Yes	No	No	Yes	No	Cyproterone for 3 months	0%	NA	NA	No	No
TAPS (2014)114	35	Yes	Yes	No	No	No	Goserelin + dutasteride for 3 months	0%	NR	17%‡	No	Yes
							Goserelin + bicalutamide + dutasteride for 3 months	10%	NR	20%‡
							Goserelin + bicalutamie + dutasteride + ketoconazole for 3 months	8%	NR	23%‡
NeoAbi (2014)53	56	Yes	Yes	No	Yes	No	LHRH agonist for 6 months + abiraterone for 3 months	4%	0%	44%	No	Yes
							LHRH agonist for 6 months + abiraterone for 6 months	10%	14%	52%
NeoEnza (2015)115	48	Yes	Yes	Yes	Yes	No	Enzalutamide for 6 months	0%	0%	36%	Yes	Yes
							Enzalutamide + dutasteride + leuprolide for 6 months	4%	13%	74%
MDACC (2016)116§	65	Yes	Yes	No	Yes	No	Abiraterone + enzalutmide + LHRH agonist for 6 months	2%	NR	NR	No	Yes
							Abiraterone + LHRH agonists for 6 months	5%
	30	Yes	Yes	Yes	Yes	Yes	Leuprolide + enzalutamide	10%	55%	NR	NA	NA
							Leuprolide + enzalutamide + abiraterone	15%	50%

ADT, androgen-derpivation therapy; LHRH, luteinizing-hormone releasing hormone; NA, not available; NR, not reported; pCR, pathological complete response; PSA, prostate specific antigen

^*Patients were stratified for Gleason score and baseline serum PSA level

^‡MRD defined as <0.2 cm³ in this study

^§Full study not reported, data were obtained from abstract.